ArticlePloS one2011
An engineered cardiac reporter cell line identifies human embryonic stem cell-derived myocardial precursors.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- Fluorescent hiPSC-derived MYH6-mScarlet cardiomyocytes for real-time tracking, imaging, and cardiotoxicity assays.Cell biology and toxicology · 2023Article
- Embryonic Stem Cells in Clinical Trials: Current Overview of Developments and Challenges.Advances in experimental medicine and biology · 2021Review
- Fluorescent PSC-Derived Cardiomyocyte Reporter Lines: Generation Approaches and Their Applications in Cardiovascular Medicine.Biology · 2020Review
- Heart regeneration with human pluripotent stem cells: Prospects and challenges.Bioactive materials · 2020Review
- A human embryonic stem cell reporter line for monitoring chemical-induced cardiotoxicity.Cardiovascular research · 2020Article
- Cardiac Regeneration with Human Pluripotent Stem Cell-Derived Cardiomyocytes.Korean circulation journal · 2018Review
- Applications of genetically engineered human pluripotent stem cell reporters in cardiac stem cell biology.Current opinion in biotechnology · 2018Review
- From Bench to Market: Preparing Human Pluripotent Stem Cells Derived Cardiomyocytes for Various Applications.International journal of stem cells · 2017Review
- Plasma microvesicle analysis identifies microRNA 129-5p as a biomarker of heart failure in univentricular heart disease.PloS one · 2017Article
- Current Strategies and Challenges for Purification of Cardiomyocytes Derived from Human Pluripotent Stem Cells.Theranostics · 2017Review
- Human stem cells from single blastomeres reveal pathways of embryonic or trophoblast fate specification.Development (Cambridge, England) · 2015Article
- Treatment with hESC-Derived Myocardial Precursors Improves Cardiac Function after a Myocardial Infarction.PloS one · 2015Article
- MicroRNA-363 negatively regulates the left ventricular determining transcription factor HAND1 in human embryonic stem cell-derived cardiomyocytes.Stem cell research & therapy · 2014Article
- Fast and efficient multitransgenic modification of human pluripotent stem cells.Human gene therapy methods · 2014Article
- Engineering the human pluripotent stem cell microenvironment to direct cell fate.Biotechnology advances · 2013Review
- MicroRNAs: a new piece in the paediatric cardiovascular disease puzzle.Cardiology in the young · 2013Review
- Induced pluripotent stem cells: the new patient?Nature reviews. Molecular cell biology · 2012Review
- Embryonic template-based generation and purification of pluripotent stem cell-derived cardiomyocytes for heart repair.Journal of cardiovascular translational research · 2012Review
- Strategies for enrichment and selection of stem cell-derived tissue precursors.Stem cell research & therapy · 2012Review
- Developmental effects of tobacco smoke exposure during human embryonic stem cell differentiation are mediated through the transforming growth factor-β superfamily member, Nodal.Differentiation; research in biological diversity · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Unlike some organs, the heart is unable to repair itself after injury. Human embryonic stem cells (hESCs) grow and divide indefinitely while maintaining the potential to develop into many tissues of the body. As such, they provide an unprecedented opportunity to treat human diseases characterized by tissue loss. We have identified early myocardial precursors derived from hESCs (hMPs) using an α-myosin heavy chain (αMHC)-GFP reporter line. We have demonstrated by immunocytochemistry and quantitative real-time PCR (qPCR) that reporter activation is restricted to hESC-derived cardiomyocytes (CMs) differentiated in vitro, and that hMPs give rise exclusively to muscle in an in vivo teratoma formation assay. We also demonstrate that the reporter does not interfere with hESC genomic stability. Importantly, we show that hMPs give rise to atrial, ventricular and specialized conduction CM subtypes by qPCR and microelectrode array analysis. Expression profiling of hMPs over the course of differentiation implicate Wnt and transforming growth factor-β signaling pathways in CM development. The identification of hMPs using this αMHC-GFP reporter line will provide important insight into the pathways regulating human myocardial development, and may provide a novel therapeutic reagent for the treatment of cardiac disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.